Daniel Morgenstern Part 2 - SKC Neuroblastoma Parent Conference 2015

Dr Daniel Morgenstern, Great Ormond Street Hospital Responses to parent questions In this presentation Dr Morgenstern provides his responses on the following topics: • How long after treatment can we know that the cancer will not return? • Are there any results from the BEACON trial? • What clinical trials are available across Europe for relapse? • GA-DOTATATE therapy and LuDo trial – what can we expect? • Has there been any progress on bringing the DFMO trial to London? • Why is it important to randomise clinical trials? CAR T-Cell Therapy for Neuroblastoma This presentation covers the novel use of Chimeric Antigen Receptor T-Cells in pioneering research into neuroblastoma. Dr Morgenstern gives a brief overview of cancer immunotherapy in relation to neuroblastoma and then discusses CAR T-cells, what they are and how they work. The discussion surrounds the process of creating the cells from the patient in details and how they may be effective in treating the disease. There is a planned trial due to open soon at Great Ormond Street Hospital aiming to assess the effectiveness and potential toxicity of this approach which is also covered.